GABA blocks pathological but not acute TRPV1 pain signals.

Hanack C, Moroni M, Lima WC, Wende H, Kirchner M, Adelfinger L, Schrenk-Siemens K, Tappe-Theodor A, Wetzel C, Kuich PH, Gassmann M, Roggenkamp D, Bettler B, Lewin GR, Selbach M, Siemens J.
Source: Cell
Publication Date: (2015)
Issue: 160(4): 759-70
Research Area:
Gene Expression
Basic Research
Cells used in publication:
Dorsal root ganglion (DRG), mouse
Species: mouse
Tissue Origin: brain
4D-Nucleofector™ X-Unit
3x10e5 mDRG cells were pellet after BSA gradient and resuspend in -20µl P3 solution -DC-100 2µg tomato reporter or GABAb1-ASAA vector 10 min post incubation in cuvette w/o media Transfection efficiency around 40%
Sensitization of the capsaicin receptor TRPV1 is central to the initiation of pathological forms of pain, and multiple signaling cascades are known to enhance TRPV1 activity under inflammatory conditions. How might detrimental escalation of TRPV1 activity be counteracted? Using a genetic-proteomic approach, we identify the GABAB1 receptor subunit as bona fide inhibitor of TRPV1 sensitization in the context of diverse inflammatory settings. We find that the endogenous GABAB agonist, GABA, is released from nociceptive nerve terminals, suggesting an autocrine feedback mechanism limiting TRPV1 sensitization. The effect of GABAB on TRPV1 is independent of canonical G protein signaling and rather relies on close juxtaposition of the GABAB1 receptor subunit and TRPV1. Activating the GABAB1 receptor subunit does not attenuate normal functioning of the capsaicin receptor but exclusively reverts its sensitized state. Thus, harnessing this mechanism for anti-pain therapy may prevent adverse effects associated with currently available TRPV1 blockers.